Screener / SEC EDGAR /CIK 0001439222 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Agios Pharmaceuticals, Inc. AGIO

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of AGIO's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter May 30, 2024
Questions asked 4 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 4 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 3 of 3 closing letter

Half the closed reviews took 24 days or less from the first letter to the closing letter.

Form 10-K

2024-05-30 to 2024-06-24 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2024-06-24
Inventory
Financial Operations Overview · Cost of Sales, page 70
SEC asked (1)
You disclose that it is your policy to expense costs associated with the manufacturing of your products prior to regulatory approval and, therefore, they are not included in costs of sales. With regards to PYRUKYND®, please tell us, and provide proposed disclosure to be included in future periodic reports, the following: • The cost of the inventory build-up prior to regulatory approval that had been expensed in
Rest of the question

prior periods as research and development expenses (i.e. zero cost inventories) • The estimated selling value of zero cost inventory on hand at December 31, 2023 and when you expect, based on your current sales trends, the zero cost inventories to be depleted • The shelf life of your inventory and your consideration of whether or not your inventory will be determined to be obsolete in future periods.

AGIO answered
We respectfully acknowledge the Staff’s comment and provide the following information in response. For your convenience, each bullet of the Staff’s comment is reproduced in bold, italicized type below, followed by our responses thereto.

The cost of inventory build-up prior to regulatory approval that had been expensed in prior periods as research and development expenses (i.e., zero-cost inventories) up until the launch of PRYUKYND® in the first quarter of 2022 was $3.0 million, and at each of December 31, 2023 and March 31, 2024, this cost was $0.4 million.
Rest of the answer

We do not consider the amounts for these periods to be significant to our financial condition or our results of operations.

Of the

$0.4 million in zero-cost inventories at December 31, 2023 and March 31, 2024, approximately $0.3 million will expire during the period ending June 30, 2024, with the remaining

$0.1 million expiring in 2025. With respect to this remaining amount of zero-cost inventory, and the corresponding estimated selling value of that inventory, we do not consider such amount to be significant to our financial condition or our results of operations.

PYRUKYND® (mitapivat) sold for the treatment of hemolytic anemia in adults with pyruvate kinase (“PK”) deficiency in the United States is manufactured in three stages: 1) bulk active pharmaceutical ingredient (“API”) manufacturing, 2) drug product manufacturing, which converts the API into tablets, and 3) labeling and packaging of the drug product into cartons, which yields a ready-to-sell finished good. After the first stage of the manufacturing process is completed, the API has an initial shelf life of 60 months from the date of manufacture. However, the end of the 60 months represents a retest date and not an expiration date. Upon completion of the second stage of the manufacturing process, the drug product has a shelf life of 36 months from the manufacture date. The labeling and packaging of the drug product in the third stage does not change the expiration date from the original 36 months from the manufacture date. We utilize third-party contract manufacturing organizations to perform each step in this manufacturing process.

On a quarterly basis, we perform an assessment to determine if there is any excess, obsolete or expired inventory and whether we need to reserve for such amounts. Based on this assessment, we have not reserved for any inventory at December 31, 2023 or March 31, 2024.

We will modify our disclosures in the Management’s Discussion and Analysis of Financial

Condition and Results of Operations sections of our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the Commission commencing with our

Quarterly Report on Form 10-Q for the period ending June 30, 2024. The changes set forth below are based on our Annual Report on Form 10-K for the period ended

December 31, 2023 (the “2023 Form 10-K”) as follows, with changes underlined:

Cost of Sales

Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND®. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND® recorded during the years ended December 31, 2023 and December 31, 2022 were expensed prior to February 17, 2022, and, therefore, are not included in costs of sales during the years ended December 31, 2023 and December 31,

2022. The amounts excluded from cost of sales were not significant during the years ended December 31, 2023 and December 31, 2022.

Inventories are reviewed periodically to identify excess or obsolete inventory based on projected sales activity as well as product shelf-life. Expired inventory is disposed of, and the related costs are recognized as cost of sales in our consolidated statement of operations, when, based on the expiry date, we do not believe we are able to sell the inventory. We have not reserved for excess or obsolete inventory during the years ended December 31, 2023 and December 31, 2022.

Read in the reply
In its next report

First report after the company's reply of Jun 11, 2024: 10-Q filed Aug 1, 2024 ↗, against the 10-Q filed May 2, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development Expenses · PYRUKYND (mitapivat): First-in-Class PK Activator, page 71
SEC asked (2)
You note that in connection with your regulatory approvals in the EU and Great Britain, you are currently providing access to PYRUKYND® free of charge for eligible patients in those jurisdictions through a global managed access program and that you may provide access to PYRUKYND® for adult patients with PK deficiency in other jurisdictions upon request through the global managed access program.
Rest of the question

Please tell us, and provide proposed disclosure to be included in future periodic reports, the following: • A robust description of the global managed access program and how your product is process through this program • Your accounting policy for the free products provided through the global managed access program • The expense incurred in each jurisdiction for the product provided free of charge through the global managed access program or a statement, if true, that the aggregated expense is not considered by management to be material • A discussion regarding your future plans and/or obstacles you have encountered to commercialize PYRUKYND® in the EU and Great Britain. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

AGIO answered
your convenience, each bullet of the Staff’s comment is reproduced in bold, italicized type below, followed by our responses thereto.

Our global managed access program (“GMAP”) is intended to provide a pathway for adult PK deficiency patients receiving care in selected countries to have access to PYRUKYND®. Healthcare providers must submit an inquiry on behalf of their patients to us for consideration when certain criteria are met.
Rest of the answer

Criteria may include, but are not limited to, the following:

The person has a current diagnosis of PK deficiency

The person is 18 years of age or older

The person does not have rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption

Sufficient supply of PYRUKYND® is readily available and supply is allowed under the local rules and regulations

Other criteria may be considered and reviewed with the treating provider based on the assessment of the person’s condition and medical history

We utilize a third-party vendor to manage our GMAP, with inventory shipped via consignment from the third-party logistics company we utilize to manage distribution of PYRUKYND®.

managed access program or a statement, if true, that the aggregated expense is not considered by management to be material

The aggregated expense associated with PYRUKYND® provided free of charge through our

GMAP is not considered by management to be significant to our financial condition or results of operations, with amounts totaling $0.1 million for the period ended March 31, 2024, $0.2 million for the year ended December 31,

2023, and less than $0.1 million for the year ended December 31, 2022.

A discussion regarding your future plans and/or obstacles you have encountered to commercialize PYRUKYND® in the EU and Great Britain.

Our disclosure included in our 2023 Form 10-K and our Quarterly Report on Form 10-Q for the period ended March 31, 2024 concluded with the following sentence ‘Beyond the global managed access program, we continue to evaluate options for the commercialization of PYRUKYND® outside of the United States, including through exploring potential partnership opportunities.’

While we believe our GMAP provides patients with an effective channel to access PYRUKYND®, we continue to assess that and other channels for patients to access PYRUKYND® in the EU and Great Britain.

Condition and Results of Operations sections of our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the Commission commencing with our

Quarterly Report on Form 10-Q for the period ending June 30, 2024. The changes set forth below are based on our 2023 Form 10-K as follows, with changes underlined:

PYRUKYND® (mitapivat):

First-in-Class PK Activator

We are developing PYRUKYND® for the treatment of PK deficiency and other hemolytic anemias such as thalassemia and SCD. PYRUKYND® is an orally available small molecule and a potent activator of the wild-type and mutated PK enzymes.

In February 2022, the FDA approved PYRUKYND® for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND® for the treatment of PK deficiency in adult patients in the EU. In December 2022, we received marketing authorization in Great Britain for

PYRUKYND® for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND® in clinical trials for the treatment of thalassemia, SCD, and in pediatric patients with PK deficiency. We have worldwide development and commercial rights to PYRUKYND® and expect to fund the future development and commercialization costs related to this program. PYRUKYND® has been granted orphan drug designation for the treatment of PK deficiency by the FDA and the EMA. Additionally, PYRUKYND® has received orphan drug designation from the FDA for the treatment of thalassemia and SCD.

We have built our commercial infrastructure to support the commercial launch of PYRUKYND® in adult PK deficiency in the United States. In connection with our regulatory approvals in the EU and Great Britain, we are currently providing access to PYRUKYND® free of charge for eligible patients in those jurisdictions through a global managed access program. We may provide access to PYRUKYND® for adult patients with PK deficiency in other jurisdictions upon request through the global managed access program, on either a free of charge or for charge basis. Our global managed access program has not had a significant impact on our business, financial condition or results of operations. Beyond the global managed access program, we continue to evaluate options for the commercialization of PYRUKYND® outside of the United States, including through exploring potential partnership opportunities.

If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 649-8600. Thank you for your assistance.

Read in the reply
In its next report

First report after the company's reply of Jun 11, 2024: 10-Q filed Aug 1, 2024 ↗, against the 10-Q filed May 2, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-06-24

Form 10-K for the Year Ended December 31, 2017

2018-07-03 to 2018-07-27 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2018-07-27
Revenue
Celgene Corporation · Accounting analysis and revenue recognition - collaboration revenue, page 13
SEC asked
Please tell us why it is appropriate to recognize royalty revenue associated with IDHIFA upon the underlying sale by Celgene. In your response explain to us how the royalty relates predominantly to the license of intellectual property as stipulated in ASC 606-1055-65A when it appears from disclosure in the first paragraph of your 2010 Agreement section on page 12 that you led discovery, preclinical and early
Rest of the question

clinical development under the collaboration with Celgene.

AGIO answered
In response to the Staff’s comment, we advise the Staff that, consistent with ASC 606-10-55-65 and 55-65A, we have concluded that it is appropriate to recognize royalty revenue associated with Celgene’s sale of IDHIFA upon the underlying sale because, as further discussed below, the license was delivered prior to the sales of IDHIFA and the royalty relates only to the license performance obligation.

Our

April 2010 discovery and development collaboration and license agreement with Celgene (“2010 Agreement”) required us to provide research services during the discovery phase of the 2010
Rest of the answer

Agreement and, if development candidates were identified, to provide development services, both preclinical and clinical, through phase 1 dose escalation clinical trials. Celgene had the option to obtain a license to certain drug candidates under the 2010 Agreement until the end of phase 1 dose escalation clinical trials. IDHIFA was one such drug candidate for which we initially led discovery, preclinical and early clinical development until phase 1 dose escalation was substantially complete, at which time Celgene exercised its option to license IDHIFA in June 2014.

Upon exercising its option to the license and the delivery of the license by us in June 2014, Celgene had the exclusive right under the 2010 Agreement to continue to develop IDHIFA at its sole discretion. Given Celgene’s extensive expertise in the oncology field, it had the ability to perform this development work on its own or through the use of a third party. We concluded the delivery of the license is distinct and a separate performance obligation from the discovery and development services. The license is necessary for Celgene to derive economic value from the underlying intellectual property and the royalty relates only to the license performance obligation. Therefore, we further concluded that the royalties and sales-based milestones in the collaboration agreement qualify for the sales-based or usage-based royalty exception defined in ASC 606-10-55-65A.

Upon the adoption of ASC 606 on January 1, 2018, we recognize royalty revenue associated with Celgene’s sale of IDHIFA consistent with ASC

606-10-55-65 through 55-65A. In accordance with ASC 606-10-55-65, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Therefore, we have recorded revenue when the related sales occurred because the performance obligation related to the delivery of the license to Celgene was previously satisfied.

In order to further enhance our disclosures, we plan to make the following changes to our Quarterly Report on Form 10-Q for the quarterly period ending

June 30, 2018, and in future filings. Below is the applicable disclosure from Note 5 of the Notes to Condensed Consolidated Financial Statements of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018, marked to show such proposed modified disclosure.

“For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Under the 2010 Agreement, we may also receive royalties at tiered, low-double digit to mid-teen percentage rates on net sales of IDHIFA®. As the underlying performance obligation, or delivery of the license to IDHIFA, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. Assuming all other revenue recognition criteria are met, royalty payments will be recognized as revenue in the period in which they are earned. During the three and six months ended March 31 June 30, 2018, we earned $1.4[•] million and [•] million, respectively, in royalty revenue under the 2010 Agreement.”

****

If you have any further questions or comments, or if you require additional information, please contact the undersigned by telephone at (617) 649-8600 or electronically at [email protected]. Thank you for your assistance.

Read in the reply
In its next report

First report after the company's reply of Jul 13, 2018: 10-Q filed Aug 2, 2018 ↗, against the 10-Q filed May 4, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-07-27

Form 10-K

2017-07-31 to 2017-08-21 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2017-08-21
Intellectual Property, page 20
SEC asked
Please expand your disclosure in future filings to include the expiry dates of your key patents. Also disclose in future filings the foreign jurisdictions where you have issued patents or pending patent applications. Refer to Item 101(c)(iv) of Regulation S-K.
AGIO answered
The Company proposes to include revised disclosure in the Intellectual Property portion of the Business section in its Annual Report on Form 10-K for the fiscal year ending December 31, 2017 regarding the Company’s patent portfolio that is consistent with the following (subject only to completing the bracketed language below):

“Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates and our core technologies, including novel biomarker and diagnostic discoveries, and other
Rest of the answer

know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary or intellectual property rights. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.

We file patent applications directed to our key product candidates, including IDHIFA®, ivosidenib, AG-881, AG-348 and AG-270, in an effort to establish intellectual property positions regarding new chemical entities relating to these product candidates as well as uses of new chemical entities in the treatment of diseases. We also seek patent protection with respect to biomarkers that may be useful in selecting the right patient population for therapies with our product candidates. As of [date] we owned or licensed [number] issued US patents, [number] US patent applications, [number] issued foreign patents, [number] foreign patent applications, and [number] pending Patent Cooperation Treaty, or PCT, patent applications. The foreign issued patent and patent applications are in a number of jurisdictions, including [include preponderance of jurisdictions across primary geographic regions].

The intellectual property portfolios for our most advanced programs as of [date] are summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO can be significantly narrowed by the time they issue, if they issue at all. We expect this could be the case with respect to some of our pending patent applications referred to below.

IDH mutant inhibitor programs

The intellectual property portfolio for our IDH mutant inhibitor programs contains patent applications directed to compositions of matter for IDHIFA®, ivosidenib, and AG-881, as well as analogs thereof, and compositions of matter for IDH mutant inhibitors with different compound families, as well as methods of use for these novel compounds and diagnostic methods for detecting various IDH1 and IDH2 mutations. As of [date], we owned [number] issued US patents, [number] issued foreign patents, [number] pending U.S. patent applications, [number] pending foreign patent applications in a number of jurisdictions, and [number] pending PCT patent applications directed to our IDH mutant inhibitor programs, including our clinical candidates. Any U.S.

or ex-U.S. issued patents or patents issuing from the pending applications covering our IDH mutant inhibitor programs will have a statutory expiration date from [year] to [year]. Patent term adjustments or patent term extensions could result in later expiration dates.

PK deficiency program

The intellectual property portfolio for our PK deficiency program contains patent applications directed to compositions of matter for AG-348, as well as analogs thereof, and compositions of matter for PKR activators with different compound families, as well as methods of use for these novel compounds. As of [date], we owned [number] issued US patents, [number] issued foreign patents, [number] pending U.S. patent applications, [number] pending foreign patent applications in a number of jurisdictions, and [number] pending PCT patent applications directed to our PK deficiency program, including our clinical candidates. Any U.S. or ex-U.S. issued patents or patents issuing from the pending applications covering our PK deficiency program will have a statutory expiration date from [year] to [year]. Patent term adjustments or patent term extensions could result in later expiration dates.

MTAP-deleted cancer program

The intellectual property portfolio for our MTAP-deleted cancer program contains patent applications directed to compositions of matter for AG-270, as well as analogs thereof and other compound families, as well as methods of use for these novel compounds and diagnostic methods for detecting MTAP deletions. As of [date], we owned [number] pending U.S.

patent applications, [number] pending foreign patent applications in a number of jurisdictions, and [number] pending PCT patent applications directed to our MTAP-deleted cancer program. Any U.S. or ex-U.S. patents issuing from the pending applications covering our MTAP-deleted cancer program will have a statutory expiration date from [year] to [year]. Patent term adjustments or patent term extensions could result in later expiration dates.

The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or the USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each medicine and other factors.

There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents.

As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, we cannot be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and file patent applications in the United States that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.

In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed through a relationship with a third party.

With respect to our proprietary cellular metabolism technology platform, we consider trade secrets and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to this technology platform, these trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.”

* * * *

If you have any further questions or comments, or if you require additional information, please contact the undersigned by telephone at (617) 649-8600 or electronically at [email protected]. Thank you for your assistance.

Read in the reply
In its next report

First report after the company's reply of Aug 11, 2017: 10-Q filed Nov 1, 2017 ↗, against the 10-Q filed May 4, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-08-21

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2017-08-07. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AGIO/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.